Andalusian Public Foundation for the management of Research in Seville
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.
Arthritis, Rheumatoid
One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb). The drugs to be administered to patients are: JAK-type kinase inhibitors. Monoclonal antibodies against TNF. Soluble receptor against TNF. Biosimilar FAMEb. Rituximab. Abatacept. Drugs that block IL6. A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.}}
Study Type : | Observational |
Estimated Enrollment : | 540 participants |
Official Title : | Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities. |
Actual Study Start Date : | April 1, 2021 |
Estimated Primary Completion Date : | December 1, 2026 |
Estimated Study Completion Date : | December 31, 2026 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Virgen Macarena University Hospital
Sevilla, Spain, 41009